GlassScriptPhysician profile
Richard D Brasington, JR.
NPI 1437176963
$100,030.52
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $13K · 2021: $17K · 2022: $26K · 2023: $5,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,650 · Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,650.00 |
| Food and Beverage | $495.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $51,511.86 | 2020-2023 | Acthar |
| Amgen INC. | $10,100.00 | 2019-2023 | Enbrel, Amjevita, Avsola |
| Mallinckrodt Enterprises LLC | $9,845.52 | 2019 | |
| Pfizer INC. | $9,561.80 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $9,418.16 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $3,750.00 | 2020-2021 | |
| Genzyme Corporation | $2,441.00 | 2019 | |
| Janssen Biotech, INC. | $2,190.04 | 2020-2023 | Tremfya |
| Abbvie INC. | $371.77 | 2019-2023 | Rinvoq, Humira |
| Astrazeneca Pharmaceuticals LP | $156.73 | 2022 | |
| Horizon Therapeutics Plc | $149.16 | 2020-2023 | Krystexxa |
| Lilly USA, LLC | $101.69 | 2020-2023 | Taltz |
| Ucb, INC. | $79.44 | 2020-2022 | |
| Glaxosmithkline, LLC. | $65.67 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $20.86 | 2023 | Uptravi, Opsumit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.01 | 2021 | |
| Zyla Life Sciences, INC. | $15.54 | 2020 | |
| Merck Sharp & Dohme LLC | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Brasington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.